Brawn Biotech Ltd (BRAWN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Brawn Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Intimation · 05 Nov 2026, 5:30 am
Brawn Biotech Board Meeting Scheduled for 5th Nov'26 to Consider Q2 Results Brawn Biotech Ltd has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the unaudited financial results for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the company's trading window for dealing in securities remains closed until 16th Nov'26 and will reopen on 17th Nov'26.
Disclosure under Regulation 30 of SEBI LODR Regulations, 2015
Others (Uncategorized) · 29 Sept 2026, 9:16 pm
Brawn Biotech Approves Statutory Auditor Appointment and Director Re-Appointment Brawn Biotech Limited announced that its members have approved key resolutions at the Annual General Meeting. The company approved the appointment of M/s. GDSM and Co., Chartered Accountants, as Statutory Auditors effective 29th Sep'26 for a tenure extending through FY31. Additionally, shareholders approved the re-appointment of Director Mr. Brij Raj Gupta, who retired by rotation. Gupta holds 500,774 equity shares in the company as of 31st Mar'26.
Scrutinizers Report attached along with voting results for 41st AGM
Annual General Meeting · 29 Sept 2026, 9:05 pm
Proceedings of 41st AGM
Annual General Meeting · 29 Sept 2026, 6:28 pm
Outcome of 41st Annual General Meeting
Annual General Meeting · 29 Sept 2026, 6:23 pm
Letters sent to shareholders as per Reg 36
Others (Uncategorized) · 02 Sept 2026, 10:16 pm
Brawn Biotech Dispatches Letters for 41st AGM and FY26 Annual Report On 2nd Sep'26, Brawn Biotech Ltd. issued letters to shareholders lacking registered email addresses, providing weblinks to access its 41st AGM Notice and FY25-26 Annual Report in compliance with SEBI Regulation 36(1)(b). Concurrently, the company notified physical shareholders of a special one-year SEBI window, active from 5th Feb'26 to 4th Feb'27, facilitating the re-lodgement of transfer deeds originally submitted prior to 1st Apr'19 that were subsequently rejected or left unattended. Shareholders can process these corrections via the company's registrar, RCMC Share Registry Pvt. Ltd.
ANNUAL REPORT FOR FY 2025-26
Others (Uncategorized) · 01 Sept 2026, 10:19 pm
Notice of 41st AGM to be held on 29.09.2026
Annual General Meeting · 01 Sept 2026, 10:15 pm
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.
Financial Result · 13 Aug 2026, 6:47 pm
Brawn Biotech Q1FY27 Results and Corporate Updates Brawn Biotech's Board approved results for the quarter ended Jun 30, '26. Revenue from operations grew 4.9% YoY to ₹607.88 lacs. Profit After Tax (PAT) declined 34.6% YoY to ₹15.44 lacs from ₹23.60 lacs. Basic EPS for the quarter stood at ₹0.52. The Board also recommended appointing M/s G D S M and Co. as Statutory Auditors for five years, subject to shareholder approval. The 41st AGM will be held via VC on Sep 29, '26 to consider these proposals.
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.
Outcome · 13 Aug 2026, 6:37 pm
Brawn Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 608 (+4.8% YoY | +207.6% QoQ) ■ EBITDA: 4.6 (-73.9% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 0.8 (-228 bps YoY | Loss to Profit QoQ) ■ PAT: 15.4 (-34.6% YoY | -73.5% QoQ) ■ EPS (INR): 0.52 (-41.6% YoY | -73.3% QoQ)
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Intimation · 13 Aug 2026, 5:30 am
Brawn Biotech Board Meeting Scheduled for Q1FY27 Results Brawn Biotech Ltd. has scheduled a Board of Directors meeting for 13 Aug'26 to consider and approve the un-audited financial results for the quarter ended 30 Jun'26. In connection with the results announcement, the trading window for insiders will remain closed until 15 Aug'26 and is set to reopen on 16 Aug'26.
Intimation regarding non-applicability of Regulation 23(9)
Others (Uncategorized) · 30 May 2026, 11:09 pm
Brawn Biotech Confirms Exemption from Related Party Transaction Filings Brawn Biotech Ltd. will not file related party transaction disclosures for the half-year ended 31st Mar'26. The company is exempt under SEBI regulations as its paid-up share capital of Rs. 3 Crore and net worth of Rs. 4.32 Crore as of 31st Mar'26 are below the specified thresholds of Rs. 10 Crore and Rs. 25 Crore, respectively. This condition has been met for the last three consecutive financial years, confirming continued non-applicability of the disclosure requirement.
The Board of Directors today in their meeting considered and approved the audited financial results for quarter and year ended 31st March 2026
Financial Result · 29 May 2026, 10:19 pm
Brawn Biotech Reports Q4FY26 Audited Financial Results Brawn Biotech announced audited results for the period ended 31 Mar'26. For Q4FY26, the company reported a net profit of ₹58.34 Lacs compared to a profit of ₹130.50 Lacs in Q4FY25. Revenue from operations for the quarter stood at ₹197.65 Lacs, a decrease from ₹577.20 Lacs YoY. For the full year FY26, net profit was ₹94.06 Lacs, a significant turnaround from a loss of ₹179.81 Lacs in FY25. FY26 revenue grew 26.1% YoY to ₹1,697.77 Lacs. Basic EPS for FY26 was ₹3.26.
Outcome of the Board Meeting of the Company held on 29th May 2026, and submissions of Audited Financial Results for the Quarter and year ended 31.03.2026
Outcome · 29 May 2026, 9:49 pm
Brawn Biotech Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 198 (-65.8% YoY | -54.2% QoQ) ■ EBITDA: -50.5 (Profit to Loss YoY | -4574.1% QoQ) ■ EBITDA Margin (%): -25.5 (Profit to Loss YoY | -2529 bps QoQ) ■ PAT: 58.3 (-55.3% YoY | +1071.5% QoQ) ■ EPS (INR): 1.95 (-55.1% YoY | +1047.1% QoQ)
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial results ....
Intimation · 29 May 2026, 5:30 am
Brawn Biotech Board Meeting Scheduled for Q4 & FY26 Results Brawn Biotech Ltd. has scheduled a Board of Directors meeting for Fri, 29 May '26, to consider and approve the audited financial results for the quarter and financial year ended 31 Mar '26. The company also noted that the trading window for insiders, which closed on 30 Mar '26, will remain shut until 31 May '26 and is set to reopen on 01 Jun '26.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 13 Apr 2026, 11:05 pm
Brawn Biotech Not Classified as a Large Corporate Under SEBI Framework Brawn Biotech Ltd. (BSE: BRAWN) has formally declared to the BSE on 13 Apr '26 that it does not qualify as a 'Large Corporate' (LC) per SEBI's framework. This determination is based on criteria outlined in SEBI circulars from 26 Nov '18 and 19 Oct '23. Consequently, the company is not subject to the mandatory fundraising requirements through debt securities applicable to LCs. The filing confirmed that the company had NIL outstanding borrowings as of 31 Mar '25.
Appointment of Internal Auditors and Secretarial Auditor for FY 2025-26.
Outcome · 25 Mar 2026, 5:28 pm
Brawn Biotech Appoints Auditors for FY25-26 Brawn Biotech announced that its Board, at the 25th Mar'26 meeting, approved key appointments for FY25-26. Mr. Viney, Practicing Company Secretary, was appointed as the Secretarial Auditor. Additionally, M/s Sahil Pasricha & Associates, Chartered Accountants, were appointed as the Internal Auditors. Both appointments are effective from 25th Mar'26 for the financial year 2025-26. These appointments were made based on the recommendation of the company's Audit Committee, signaling routine changes in compliance and internal controls oversight.
OUTCOME OF BOARD MEETING HELD ON TODAY
Outcome · 14 Feb 2026, 7:58 pm
Brawn Biotech Reports Q3 FY26 Results, Profit Rebounds YoY Brawn Biotech reported Q3 FY26 results with a profit of ₹4.98 lacs, a significant turnaround from a loss of ₹43.18 lacs YoY. Revenue from operations for the quarter ended 31st Dec'25 stood at ₹431.26 lacs, a 12.1% YoY increase from ₹384.48 lacs. QoQ, revenue decreased by 11.8% from ₹489.10 lacs, and profit fell 30.3% from ₹7.14 lacs. Total expenses were ₹435.37 lacs, up 1.8% YoY but down 11.3% QoQ. Basic EPS for the quarter was ₹0.17.
Unaudited Financial Results for quarter and nine months ended 31.12.2025
Financial Result · 14 Feb 2026, 7:50 pm
BRAWN BIOTECH LTD. - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lacs) ■ Revenue: 431 (+12.2% YoY | -11.8% QoQ) ■ EBITDA: -1.1 (+97.3% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -0.3 (+1020 bps YoY | Profit to Loss QoQ) ■ PAT: 5.0 (Loss to Profit YoY | -30.3% QoQ) ■ EPS (INR): 0.17 (Loss to Profit YoY | -32.0% QoQ)
Prior Intimation for Board Meeting scheduled to be held on 14th February, 2026 to consider and approve unaudited financial results for the quarter ended 31st December, 2025.
Others (Uncategorized) · 06 Feb 2026, 10:56 pm
Brawn Biotech Board Meeting on 14th Feb'26 for Q3FY26 Results Brawn Biotech has scheduled a Board of Directors meeting on 14th Feb'26 to consider and approve the unaudited financial results for the quarter ended 31st Dec'25. In line with this, the trading window for insiders, which closed on 27th Dec'25, will remain closed until the end of business on 16th Feb'26. The window will subsequently reopen for trading on 17th Feb'26.
Appointment of Chief Financial Officer.
Change in Management · 30 Jan 2026, 6:06 pm
Brawn Biotech Appoints Rati Garg as Chief Financial Officer Brawn Biotech Ltd. has appointed Ms. Rati Garg as Chief Financial Officer and Key Managerial Personnel, effective from 1st Feb'26. The appointment was approved by the Board of Directors on 30th Jan'26, based on the Nomination and Remuneration Committee's recommendation. Ms. Garg is a qualified Cost Accountant with over 15 years of experience in financial management, cost control, budgeting, FP&A, and regulatory compliance.
Resignation of Ms. Pooja Pandey (CFO and KMP).
Change in Management · 05 Jan 2026, 11:46 pm
Brawn Biotech CFO Pooja Pandey Resigns Effective Jan'26 Brawn Biotech Ltd. announced the resignation of Ms. Pooja Pandey, Chief Financial Officer and Key Managerial Personnel, effective from the close of business on 05 Jan'26. The company stated the resignation is due to personal reasons and confirmed there are no other material reasons for her departure.
General Announcement
Others (Uncategorized) · 29 Dec 2025, 10:05 pm
Brawn Biotech Director Mrs. Brij Bala Gupta Resigns Brawn Biotech Ltd. announced the resignation of Director Mrs. Brij Bala Gupta, effective 25 Nov'25. The reason cited was "pre-occupation and certain unavoidable circumstances." The company confirmed there are no other material reasons for her departure. Mrs. Gupta was not a member of any board committees prior to her resignation.
ADDITIONAL DETAILS REQUIRED FOR CORPORATE ANNOUNCEMENT UNDER REGULATION 30
Change in Management · 22 Dec 2025, 11:48 pm
Brawn Biotech Director Resigns, Cites Personal Reasons Brawn Biotech Ltd. announced the resignation of Director Mrs. Brij Bala Gupta from the Board of Directors, effective 25 Nov'25. The company received her resignation letter on 22 Dec'25. Mrs. Gupta cited "pre-occupation and certain unavoidable circumstances" as the reason for her departure. The company confirmed there are no other material reasons for the resignation. Prior to leaving, Mrs. Gupta was not a member of any board committees.
Disclosure under regulation 30 of the SEBI (LODR) Regulations for resigantion of Director
Change in Management · 25 Nov 2025, 9:00 pm